UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000046000
Receipt number R000052508
Scientific Title Evaluation for the effectiveness of Sacubitril-valsartan for acute type B aortic dissection.
Date of disclosure of the study information 2021/12/01
Last modified on 2021/11/07 01:22:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation for the effectiveness of Sacubitril-valsartan for acute type B aortic dissection.

Acronym

Evaluation for the effectiveness of Sacubitril-valsartan for acute type B aortic dissection.

Scientific Title

Evaluation for the effectiveness of Sacubitril-valsartan for acute type B aortic dissection.

Scientific Title:Acronym

Evaluation for the effectiveness of Sacubitril-valsartan for acute type B aortic dissection.

Region

Japan


Condition

Condition

Acute type B aortic dissection

Classification by specialty

Cardiology Vascular surgery Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We evaluate the efficacy for renal function and respiratory function of Sacubitril-valsartan in conservative treatment of acute type B aortic dissection.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

We evaluate the change of renal function during the conservative treatment of aortic dissection for a week after the onset.
Blood tests and urine samples will be evaluated.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Sacubitril-valsartan will be administered for a week after the onset additionally to the basic anti-hypertensive medicine.

Interventions/Control_2

Control group. Patients will be treated with anti-hypertensive medicine without sacubitril-valsartan.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with acute type B aortic dissection who are treated with conservative antihypertensive treatment

Key exclusion criteria

Complicated cases necessitate emergent or urgent surgery, patients with dialysis, patients who cannot take medicine orally, patients who cannot accept the informed consent

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Tatsuya
Middle name
Last name Watanabe

Organization

Kawasaki Medical School General Medical Center

Division name

Department of General Surgery

Zip code

7008505

Address

2-6-1, Nakasange, Kita

TEL

0862252111

Email

kosaka.r@med.kawasaki-m.ac.jp


Public contact

Name of contact person

1st name Kotone
Middle name
Last name Tsujimoto

Organization

Kawasaki Medical School General Medical Center

Division name

Department of General Surgery

Zip code

7008505

Address

2-6-1, Nakasange, Kita

TEL

0862252111

Homepage URL


Email

kosaka.r@med.kawasaki-m.ac.jp


Sponsor or person

Institute

Kawasaki Medical School General Medical Center

Institute

Department

Personal name



Funding Source

Organization

Kawasaki Medical School General Medical Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

The Sakakibara Heart Institute of Okayama

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kawasaki Medical School General Medical Center

Address

2-6-1, Nakasange, Kita, Okayama, 7008505

Tel

0862252111

Email

kosaka.r@med.kawasaki-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

川崎医科大学総合医療センター(岡山県)、心臓病センター榊原病院(岡山県)


Other administrative information

Date of disclosure of the study information

2021 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2021 Year 11 Month 01 Day

Date of IRB


Anticipated trial start date

2021 Year 12 Month 01 Day

Last follow-up date

2026 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 11 Month 07 Day

Last modified on

2021 Year 11 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052508


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name